Clinical Trials
22 trialsNCT02254278 2026-05-22
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NRG Oncology
Phase 2 Completed
NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed
NCT00875849 2025-09-30
AACER
Centre Antoine Lacassagne
Phase 2 Completed
NCT00665392 2025-08-01
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00833261 2020-08-21
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01175980 2020-08-03
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02123511 2019-04-30
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT01316757 2018-02-26
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00423930 2017-08-18
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00376987 2017-05-30
Zinc Supplements in Lowering Cadmium Levels in Smokers
Wake Forest University Health Sciences
Phase 2 Completed
NCT01256385 2017-03-27
MAESTRO HN
National Cancer Institute (NCI)
Phase 2 Completed
NCT02007200 2016-10-24
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00458978 2015-05-05
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00114283 2015-04-15
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00330382 2014-12-19
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00507767 2014-10-01
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103259 2014-05-23
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Completed
NCT00513435 2014-04-30
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00101335 2013-07-11
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Fox Chase Cancer Center
Phase 2 Completed
NCT00096512 2013-02-28
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00033618 2013-02-27
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Completed